Transcript
Page 2: Neuropharmacology: Opiates

Goals

History

Examples

Pharmacodynamics

Treatment

Epidemiology

Page 3: Neuropharmacology: Opiates

Terminology

• Opiate: family of substances• Narcotic: class of drugs including opiates• Opioid: family receptors• Analgesics: drugs that decrease pain without

unconsciousness• Anesthetic: drugs that decrease pain with

unconsciousness• Naloxone (Narcan): short acting opioid antagonist

• Naltrexone: long-acting opioid antagonist

Page 4: Neuropharmacology: Opiates

History129-199 1783-1841

1817-1884

Page 5: Neuropharmacology: Opiates

Widespread use of morphine in US between 1865-1906

Mrs. Winslow's Soothing Syrup was an indispensable aid to mothers and child-care workers. Containing one grain (65 mg) of morphine per fluid ounce, it effectively quieted restless infants and small children. It probably also helped mothers relax after a hard day's work. The company used various media to promote their product, including recipe books, calendars, and trade cards such as the one shown here from 1887 (A calendar is on the reverse side.).

Source: Prof. Anagnostaras, UCSD

Page 6: Neuropharmacology: Opiates

Origin Chemistry Schedule

Morphine Opium

poppyII (II-III)

Heroin Felix Hoffman, Bayer

Production in 1898

Acetyl=OCOH3

OH to Acetyl

Diacetylmorphine

I

Oxycodone Synthesized in 1916, Oxycontin produced in 1995

H to OH

OH to =OII (II-IV)

Codeine Identified in 1832? -OH to 0CH3

MethylmorphineII

(III-IV)

Page 7: Neuropharmacology: Opiates

History

Source: Prof. Anagnostaras, UCSD

In the following years, Heroin was a drug marketed by Bayer as a cough syrup without the nasty side effects of morphine.

Page 8: Neuropharmacology: Opiates

Potency (x-axis) vs. Efficacy (y-axis)

100

75

50

25

1Log dose (mg)

10 100

HydromorphineMorphineCodeineAspirin

Response

Page 9: Neuropharmacology: Opiates

Safety

• Effective Dose

ED50 - Dose that produces an effect in 50% of a population

Lethal/Toxic Dose

LD50 - Dose that kills 50% of a population

• Safety Factor

LD50 /ED50

Drug B100

50

Log drug doseLow HighED50 TD50

100Drug A

50

Low HighLog drug doseED50 TD50

Page 10: Neuropharmacology: Opiates

Pharmacodynamics

• Opioid Receptors• Mu: • Kappa:• Delta:

Page 11: Neuropharmacology: Opiates

Delta Opioid Receptor

Page 12: Neuropharmacology: Opiates

Delta Opiate Receptor

Tradham (2011) Trends in Pharmacological Science, 32, 581-590.

Page 13: Neuropharmacology: Opiates

Mu Receptor Distribution

Page 14: Neuropharmacology: Opiates

Kappa Opiate Receptor

Page 15: Neuropharmacology: Opiates

More terminology

• Pro- larger precursor proteins (peptides)

• Protease- enzyme that cut propeptide

Page 16: Neuropharmacology: Opiates

Endogenous Substances

Page 17: Neuropharmacology: Opiates

Knock-out

• Knock-out: animal with gene made inoperative

• Allele: alternative forms of gene

• Diploid: organism with two sets of genes for each trait

• Homozygote: +/+ or -/-• Heterozygote: +/-

Genotype Response

+/+ Full

+/- Partial

-/- Absent

C57 Mouse

Page 18: Neuropharmacology: Opiates

KO Example

• Different opiate receptor (OR) knock-outs were tested

• Male and female mice were placed on hot plate and time until jumping was recorded.

• Filled Star: p < .05 sex difference within genotype (e.g. 1 vs. 2)

• Open Star: p < .05 genotype difference within sex (e.g. 1 vs. 3)

• What do you conclude?

Martin, M. (2003). Eur J. Neurosci 17, 701-708.

1 2 3 4

Page 19: Neuropharmacology: Opiates

KO Example

• Some evidence for sex difference A,D vs. B,C.

• Mu opiate receptor is important for thermal pain (males).

• Other receptors also play a role in females.

Martin, M. (2003). Eur J. Neurosci, 17, 701-708.

A

B

C

D

Page 20: Neuropharmacology: Opiates

Comparison of Opioid Receptors

Receptor Ligand Location Function

Mu Endorphin Striatum, NAc, PAG Analgesia

Delta Enkepahlin Striatum, NAc, spinal cord Analgesia, olfaction

Kappa Dynorphin Striatum, NAc,hypothalamus Temperature

PAG: periaqueductal grayNAc: nucleus accumbens

Page 21: Neuropharmacology: Opiates

Periaqueductal Gray

• Midbrain structure

• Near cerebral aqueduct

Page 22: Neuropharmacology: Opiates

OppositesEffect Administration Withdrawal

Temperature Hypothermia Hyperthermia

Blood pressure ↓ ↑

Pupils constriction dilation

Breathing depressed panting/yawning

Pain ↓ ↑

Arousal relaxed restless

G.I. function constipation diarrhea

Sex ↓ sex drive Spontaneous

ejaculation

Mood euphoria depression

Grilly, D.M. (1998). Drugs and human behavior. Allyn: Needham Heights.

Page 23: Neuropharmacology: Opiates

Dopamine & Behavior

Murphy et al. J Neurochem (2001) 79, 626-635.

Mice of different strains: C57 (black), 129SV (white), and DBA2 (grey) received 3 mg/kgof morphine or saline (arrows). Motor-activity (left) and dopamine in the striatum (right) was recorded.

Page 24: Neuropharmacology: Opiates

Naltrexone

• The opiate antagonist naltrexone (5 ng/kg) blocks the conditioned place preference to morphine (5 mg/kg).

• Conditioned Place Preference (CPP)

– Pretest: Drug Treatment– Test: no Drug, animals

choose whether to spend time in environment associated with drug injections

Olmstead et al. (2005). Psychopharm, 181, 576-81.

Page 25: Neuropharmacology: Opiates

Codeine Addiction

• Codeine -----> Morphine• Fluoxetine inhibits 2D6• Will fluoxetine help

codeine addicts reduce their use?

• All groups reduced codeine intake by >40%.

2D6

Daily dose of codeine in people that receivedcounseling and fluoxetine (circles), quinidine (triangles), or placebo (squares).

Fernandes et al. (2002). J Clin Psychopharm, 22, 326-329.

Page 26: Neuropharmacology: Opiates

Opiate Addiction Therapies

• Narcotics Anonymous: 12 step program, limited effectiveness

• Methadone: long-acting opiate agonist (oral)

• LAAM: L-alpha-acetyl-methadol: longer acting opiate agonist

Page 27: Neuropharmacology: Opiates

Tx: Methadone

• Pill form used to prevent opiate withdrawal

• Pros: limits use of other opiates

• Cons: philosophical

Page 28: Neuropharmacology: Opiates

Epidemiology (MtF)

Page 29: Neuropharmacology: Opiates

Epidemiology: Heroin

MTF: http://www.monitoringthefuture.org/pubs/occpapers/occ63.pdf

Page 30: Neuropharmacology: Opiates

Epidemiology: Heroin

MTF: http://www.monitoringthefuture.org/pubs/occpapers/occ63.pdf

Page 31: Neuropharmacology: Opiates

Epidemiology: Vicodin

MTF: http://www.monitoringthefuture.org/pubs/occpapers/occ63.pdf

Page 32: Neuropharmacology: Opiates

Urban vs. Rural

Page 33: Neuropharmacology: Opiates

Epidemiology: College Plans

MTF: http://www.monitoringthefuture.org/pubs/occpapers/occ63.pdf

Page 34: Neuropharmacology: Opiates

Epidemiology: Non-Heroin

MTF: http://www.monitoringthefuture.org/pubs/occpapers/occ63.pdf

Page 35: Neuropharmacology: Opiates

Celebrity Overdoses

1943-19701979-2008 1964-1997

1943-1971

1949-1982 1960-1988

Page 36: Neuropharmacology: Opiates

Celebrity Overdoses

1943-19701979-2008 1964-1997

1943-1971

Heath Ledger Janis Joplin Chris Farley Jim Morrison

1949-1982 1960-1988

John Belushi Jean-Michel Basquiat

Page 37: Neuropharmacology: Opiates

Overdose

Page 38: Neuropharmacology: Opiates

Summary

• History/Examples

• Pharmacodynamics: Mu, Delta, Kappa

• Epidemiology

3 min: http://www.npr.org/player/v2/mediaPlayer.html?action=1&t=1&islist=false&id=12131233&m=12131234